Olin Corporation
OLN
$15.54
+4.09%
Olin Corporation is a 130-year-old basic materials company operating in the chemicals industry, structured around three reportable segments: Chlor Alkali Products and Vinyls (roughly 55% of sales), Epoxies (~20%), and Winchester ammunition (~25%). It is the world's largest chlor-alkali producer by capacity and pairs that commodity-chemical scale with the uniquely differentiated Winchester brand, a leading US ammunition manufacturer, giving it a dual identity versus pure-play chemical peers. The current investor narrative is dominated by the announced merger of equals with Huntsman, which cleared US antitrust review in September 2026, even as weak chemical demand and a deeply negative earnings trajectory keep sentiment cautious. With the stock down sharply over the past year, the debate centers on whether consolidation-driven cost synergies and a cyclical chlor-alkali recovery can offset a severe margin compression cycle and a recently reported quarterly loss.…
OLN
Olin Corporation
$15.54
Related headlines
Investment Opinion: Should I buy OLN Today?
The synthesized recommendation is Hold, with a cautious bias. The core thesis is that Olin is a deep-value cyclical play with significant upside if the merger synergies and chemical recovery materialize, but the near-term risks are substantial, and the stock is in a pronounced downtrend. The analyst consensus rating of 'hold' (mean 2.87) and average target price of $20.20 (35.7% upside) suggest that the sell-side sees limited near-term catalysts but recognizes the potential for a rebound.
Supporting evidence for a Hold includes the extremely low valuation (PS of 0.352x, PB of 1.298x), strong free cash flow generation ($247.9 million TTM), and the strategic merger with Huntsman that could unlock cost synergies. However, the negative net margin (-0.63%), operating margin of just 1.67%, and gross margin of 7.40% (down from 14.46% in Q2 2024) highlight the earnings challenge. The forward PE of 24.92x on estimated EPS of $1.429 implies a recovery that is not yet visible in the financials. The stock's 40% decline over the past year and its position near the 52-week low reflect deep pessimism, but also the risk of further downside if estimates are cut.
Key risks that could invalidate the thesis include a continued decline in chlor-alkali pricing, failure to achieve merger synergies, and balance-sheet stress due to high leverage (debt-to-equity of 1.707). The rating would upgrade to Buy if the stock breaks above $20 and gross margins recover above 10%, or if the merger delivers tangible synergies ahead of schedule. It would downgrade to Sell if the stock breaks below $14.82 and gross margins fall below 5%. Relative to its history, the stock is undervalued on a price-to-sales and price-to-book basis, but the market is pricing in a distressed scenario. Fair value is likely in the $18-$22 range, assuming a modest recovery.
Sign up to view all
OLN 12-Month Price Forecast
Olin presents a classic deep-value cyclical opportunity, but the timing is uncertain. The stock is trading at distressed multiples, and the merger with Huntsman could be a transformative catalyst, yet the near-term financials are weak, with negative earnings and collapsing margins. The neutral stance reflects the balance between significant upside potential if the cycle turns and substantial downside risk if it doesn't. I would upgrade to bullish if gross margins recover above 10% and the stock breaks above $20, and downgrade to bearish if it breaks below $14.82 with no improvement in fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Olin Corporation's 12-month outlook, with a consensus price target around $19.25 and implied upside of +23.9% versus the current price.
Average Target
$19.25
0 analysts
Implied Upside
+23.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$15 - $30
Analyst target range
Coverage is solid with 15 analysts, but sentiment is decidedly neutral-to-cautious: the consensus recommendation is "hold" with a recommendation mean of 2.87 (where 3.0 is Hold), and the average target price of $20.20 implies roughly +35.7% upside from the current $14.89 price. That upside looks attractive in isolation, but it is largely a function of how far the stock has fallen rather than enthusiastic conviction, and the recent institutional ratings flow shows no upgrades — Wells Fargo, Citigroup, Mizuho, BMO Capital, Morgan Stanley, Truist, KeyBanc, and RBC all reiterated existing stances (mostly Neutral/Hold/Market Perform, with Morgan Stanley at Underweight and KeyBanc at Overweight) between January and March 2026. The consensus therefore leans neutral, with the bull and bear camps roughly balanced and the average target reflecting a modest recovery rather than a re-rating. The target range is wide — $16.00 low to $30.00 high against a $20.20 average — signaling high uncertainty about the earnings recovery and merger outcome. The high target of $30.00, essentially the 52-week high, would require a full cyclical recovery in chlor-alkali and epoxy pricing plus successful merger integration and multiple expansion back toward historical norms; the low target of $16.00, only about 7.5% above the current price, prices in continued margin compression, weak chemical demand, and limited synergy realization. The spread of $14.00 between low and high targets is unusually wide for a large-cap chemical name and reflects genuine disagreement about whether 2026 estimates of $1.429 in EPS (range $0.916 to $1.792) are achievable; the fact that the stock trades below even the lowest analyst target suggests the market is pricing outcomes more bearish than the sell-side consensus, a classic setup for either a sharp relief rally on any positive catalyst or further capitulation if estimates are revised lower.
Bulls vs Bears: OLN Investment Factors
The bear case currently has stronger evidence, driven by a severe margin collapse, negative earnings, and a stock pinned near its 52-week low with no signs of stabilization. The bull case rests on deep value multiples, merger synergies, and a cyclical recovery that has yet to appear in the financials. The single most important tension is whether the chlor-alkali and epoxy markets recover enough to restore profitability before the balance sheet or liquidity becomes a constraint. If the merger integration delivers synergies and chemical demand stabilizes, the stock could re-rate sharply; if not, further downside is likely.
Bullish
- Deep value on sales and book: OLN trades at a price-to-sales ratio of just 0.352x and a price-to-book of 1.298x, both near multi-year lows (PS was 4.37x in Q1 2024, PB 3.29x). For a company with over $6.7 billion in annual revenue and a unique asset base, these multiples imply the market is pricing in a permanent impairment rather than a cyclical trough.
- Merger synergies with Huntsman: The merger of equals with Huntsman cleared US antitrust review in September 2026, removing a major regulatory hurdle. The combined entity is expected to generate significant cost synergies, and the deal appears more favorable to Olin, as evidenced by Huntsman shares sliding nearly 6% on the announcement while Olin's stock held relatively steady.
- Strong free cash flow generation: Despite a net loss, Olin generated $247.9 million in trailing free cash flow and $258.4 million in Q4 2025 alone, supported by $321.2 million of operating cash flow. This cash generation provides a cushion to fund dividends, capex, and merger integration costs without immediate balance-sheet stress.
- Analyst target implies large upside: The average analyst target price of $20.20 implies 35.7% upside from the current $14.89, and the high target of $30.00 (near the 52-week high) suggests a full cyclical recovery could more than double the stock. The wide target range ($16-$30) reflects high uncertainty but also significant potential if earnings recover.
Bearish
- Severe margin collapse: Gross margin plummeted to 1.88% in Q4 2025 from 10.71% in Q3 and 9.04% in Q1, while the trailing gross margin of 7.40% is down roughly 700 basis points from 14.46% in Q2 2024. The operating margin is just 1.67%, and net margin is -0.63%, indicating the core business is barely profitable at current pricing levels.
- Negative earnings and cash burn risk: Q4 2025 net income was -$85.7 million (EPS -$0.75), a sharp reversal from +$43.0 million in Q3. With interest expense of $46.2 million per quarter and thin operating cushion, continued losses could pressure liquidity, especially with only $167.6 million in cash and a debt-to-equity ratio of 1.707.
- Falling knife technicals: The stock is down 40.08% over the past year and 48.57% over six months, trading just 0.9% above its 52-week low of $14.82. The 1-month decline of 14.72% and 3-month decline of 28.00% show accelerating selling pressure, with relative strength versus SPY at -16.84 (1-month) and -31.13 (3-month), indicating active capital rotation out of the name.
- High leverage and weak returns: Debt-to-equity is 1.707, the current ratio is only 1.210, and ROE is -2.33% with ROA of 1.07%. The balance sheet lacks a fortress-like cushion, and the merger will add Huntsman's debt, potentially increasing financial risk if synergies are delayed.
OLN Technical Analysis
Olin is in a pronounced, sustained downtrend, with the shares down 40.08% over the trailing year and 48.57% over six months, a decline that has left the current price of $14.89 essentially pinned to its 52-week low of $14.82 — trading at just 0.9% above that floor and only 48.9% of the way up from the low to the 52-week high of $30.46. This positioning near the bottom of the range, combined with a max drawdown of -50.6%, signals a falling-knife profile rather than a value opportunity, and the stock has lost roughly half its value from peak levels. The trend is unambiguous: every major lookback window is negative, and the stock is not showing the base-building behavior typically seen before a durable reversal. Short-term momentum is deteriorating further, with a 1-month decline of 14.72% and a 3-month decline of 28.00%, meaning the pace of selling has accelerated rather than stabilized. This is a clear bearish divergence from the broader market: SPY gained 2.12% over the past month and 3.13% over three months, producing relative strength readings of -16.84 (1-month) and -31.13 (3-month) — severe underperformance that indicates capital is actively rotating out of the name. The 1-month weakness confirming the 1-year downtrend argues against a mean-reversion bounce and instead points to persistent distribution, with the short ratio of 4.85 suggesting bears remain firmly positioned. Key technical levels are tightly defined: support sits at the 52-week low of $14.82, just $0.07 below the current $14.89 price, while resistance is the 52-week high of $30.46. A breakdown below $14.82 would open fresh downside with no visible structural floor, whereas reclaiming even the mid-$20s would require a decisive change in the fundamental narrative; with a beta of 1.226, the stock is roughly 23% more volatile than the market, meaning position sizing should account for amplified moves in both directions. The 4.28 million share volume and 4.61% single-day drop on the latest print underscore that selling pressure remains active rather than exhausted.
Beta
1.23
1.23x market volatility
Max Drawdown
-51.2%
Largest decline past year
52-Week Range
$15-$30
Price range past year
Annual Return
-31.5%
Cumulative gain past year
| Period | OLN Return | S&P 500 |
|---|---|---|
| 1m | -7.6% | -1.2% |
| 3m | -33.0% | +3.4% |
| 6m | -41.9% | +7.0% |
| 1y | -31.5% | +14.4% |
| ytd | -27.9% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
OLN Fundamental Analysis
Olin's revenue trajectory has flatlined and is now rolling over: the most recent quarter (Q4 2025) posted revenue of $1.665 billion, down 0.37% year over year, following $1.713 billion in Q3 2025, $1.758 billion in Q2 2025, and $1.644 billion in Q1 2025 — a sequence that shows no growth and a modest sequential fade into year-end. Segment data shows Chlor Alkali Products and Vinyls at $856.4 million, Winchester at $449.4 million, and Epoxies at $359.3 million, meaning the commodity chlor-alkali business remains the dominant swing factor for the consolidated top line. With full-year 2026 revenue estimates averaging $7.578 billion (range $7.241 billion to $8.438 billion), the market is not pricing a meaningful demand recovery, and the investment case now hinges almost entirely on merger synergies rather than organic growth. Profitability has deteriorated sharply: Q4 2025 net income was -$85.7 million (EPS -$0.75) versus +$43.0 million in Q3 2025 and +$1.4 million in Q1 2025, and gross margin collapsed to 1.88% in Q4 from 10.71% in Q3 and 9.04% in Q1. The trailing net margin is -0.63% and the operating margin is just 1.67%, with gross margin of 7.40% far below the 14.46% recorded in Q2 2024 — a compression of roughly 700 basis points that reflects weak pricing and poor cost absorption in chlor-alkali and epoxy markets. The Q4 gross profit of just $31.3 million on $1.665 billion of revenue, alongside $46.2 million of quarterly interest expense, illustrates how thin the operating cushion has become relative to the fixed cost base. The balance sheet carries meaningful leverage: debt-to-equity is 1.707, the debt ratio is 0.463, and the current ratio of 1.210 leaves limited liquidity headroom, while ROE of -2.33% and ROA of 1.07% confirm weak capital returns. Positively, trailing free cash flow of $247.9 million and Q4 free cash flow of $258.4 million show the business can still generate cash, supported by $321.2 million of operating cash flow and $125.7 million of D&A, though capital expenditures of $62.8 million and $22.8 million of dividends consumed a portion of that. With cash of only $167.6 million against a 1.707 debt-to-equity ratio, Olin depends on internally generated cash and refinancing access rather than a fortress balance sheet, making the merger's balance-sheet combination a critical part of the credit and equity story.
Quarterly Revenue
$1.7B
2025-12
Revenue YoY Growth
-0.4%
YoY Comparison
Gross Margin
1.9%
Latest Quarter
Free Cash Flow
$247900000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is OLN Overvalued?
Because Olin's trailing net income is negative (EPS of -$0.018 and trailing PE of -56.30x), the PE ratio is not meaningful, so the appropriate primary metric is the price-to-sales ratio of 0.352x, supplemented by EV/Sales of 0.747x and EV/EBITDA of 8.59x. The forward PE of 24.92x against estimated EPS of $1.429 implies the market expects a sharp earnings recovery from the current loss, and the wide gap between the meaningless trailing PE and the positive forward multiple captures exactly how much of the valuation rests on a cyclical rebound plus merger synergies. The PEG ratio of 0.402 and price-to-cash-flow of 5.03 suggest that on cash-based measures the stock is not expensive, but the earnings-based optics remain challenged. Peer comparison is difficult given the absence of a supplied industry-average multiple set, but the absolute levels are instructive: a PS of 0.352x and EV/Sales of 0.747x are low in absolute terms for a company with $6.7 billion-plus of annual revenue, while EV/EBITDA of 8.59x is a mid-single-digit-to-high-single-digit multiple typical of late-cycle commodity chemicals. The premium or discount versus peers cannot be quantified from the provided data — industry averages are not available — but the market is clearly applying a distressed multiple, consistent with a company posting a -0.63% net margin and 1.67% operating margin versus the 10%+ operating margins Olin earned in 2022. Historical context is stark: Olin's PS ratio has compressed from 4.37x in Q1 2024 and 3.53x in Q3 2024 to 0.352x today, and its PB ratio has fallen from 3.29x in Q1 2024 to 1.298x now, placing both metrics near multi-year lows. The historical PE band is unusable because earnings have swung between positive and negative, but the PB and PS compression tells a clear story: the market has repriced Olin from a mid-cycle chemical compounder to a distressed, low-multiple cyclical, meaning either deep value or justified skepticism about the durability of earnings power.
PE
-56.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 4x~37x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are acute: Olin's Q4 2025 gross margin collapsed to 1.88% from 10.71% in Q3, resulting in a net loss of $85.7 million and EPS of -$0.75. With interest expense of $46.2 million per quarter and only $167.6 million in cash, the company has limited liquidity headroom, especially with a debt-to-equity ratio of 1.707 and a current ratio of 1.210. The business is highly sensitive to chlor-alkali pricing, which represents roughly 55% of sales, and any further deterioration could lead to covenant pressure or dividend cuts. Additionally, the merger with Huntsman will add integration risk and potentially more debt, making the balance sheet a key concern.
Market and competitive risks include the stock's high beta of 1.226, meaning it is 23% more volatile than the market, and its severe underperformance with a 1-year relative strength of -56.08 versus SPY. The chemicals sector is cyclical, and weak demand could persist, keeping margins depressed. Valuation compression risk is evident: the PS ratio has fallen from 4.37x in Q1 2024 to 0.352x, and if earnings fail to recover, the stock could remain in a low-multiple trap. Regulatory approval of the Huntsman merger removes one hurdle, but integration challenges and potential antitrust conditions could still weigh on sentiment. Competitive pressures from lower-cost producers and global overcapacity in chlor-alkali could limit pricing power.
In a worst-case scenario, a continued decline in chemical demand, failure to realize merger synergies, and a breach of debt covenants could drive the stock below its 52-week low of $14.82. The analyst low target of $16.00 is only 7.5% above the current price, but if estimates are cut, the stock could fall to $10-$12, representing a 20-33% loss from the current $14.89. The max drawdown of -50.6% over the past year shows how quickly the stock can lose value. A realistic downside target in a severe recession would be the 52-week low of $14.82, but a break below that could open a decline to $10, implying a 33% loss from current levels.
FAQ
The key risks include: 1) Financial risk: high debt-to-equity of 1.707 and only $167.6 million in cash, with negative earnings and thin margins, raising concerns about liquidity and covenant compliance. 2) Operational risk: gross margin collapsed to 1.88% in Q4 2025, and the core chlor-alkali business (55% of sales) is highly cyclical and sensitive to pricing. 3) Merger risk: the Huntsman merger, while approved, could face integration challenges and may not deliver expected synergies, potentially increasing leverage. 4) Market risk: the stock has a beta of 1.226 and has underperformed the S&P 500 by 56% over the past year, and further sector rotation out of chemicals could pressure the shares. These risks are ranked from most severe (financial) to least (market), but all are significant.
Our 12-month forecast has three scenarios: bull case (25% probability) with a target range of $26-$30, driven by a cyclical recovery and successful merger synergies; base case (50% probability) with a target range of $18-$22, assuming gradual stabilization and EPS around $1.43; and bear case (25% probability) with a target range of $10-$14, if demand weakens further and merger integration falters. The base case is most likely, with the key assumption that chlor-alkali pricing stabilizes and the company meets analyst estimates. The average analyst target of $20.20 aligns with our base case. However, the wide range reflects high uncertainty, and investors should monitor margin trends and merger progress closely.
OLN appears undervalued on asset and sales-based metrics. Its price-to-sales ratio of 0.352x is far below its historical average of over 3x in 2024, and its price-to-book of 1.298x is also near multi-year lows. The forward PE of 24.92x looks high, but that is because earnings are depressed; on a normalized basis, the stock is cheap. The market is pricing in a distressed scenario, with a trailing PE of -56.30x due to negative earnings. Compared to peers, the valuation is likely at a discount, but without industry averages, it's hard to quantify. The low PS and PB suggest the market expects a prolonged downturn, so if earnings recover, the stock could re-rate significantly.
OLN is a high-risk, high-reward deep-value play that may appeal to contrarian investors. The stock trades at just 0.352x sales and 1.298x book, near multi-year lows, and the average analyst target of $20.20 implies 35.7% upside. However, the company is currently unprofitable with a net margin of -0.63% and a gross margin of only 1.88% in the latest quarter, and the stock is in a severe downtrend, down 40% over the past year. The biggest downside risk is a break below the 52-week low of $14.82, which could lead to further losses. For investors with a long time horizon and tolerance for volatility, it could be a good buy if they believe in the cyclical recovery and merger synergies; otherwise, it is a hold at best.
OLN is more suitable for long-term investment, given its cyclical nature and the time needed for the merger synergies and chemical recovery to materialize. The stock has a beta of 1.226, indicating higher volatility than the market, and it has a dividend yield of 3.84%, which may appeal to income investors, though the payout ratio is negative due to losses. Short-term trading is risky because the stock is in a downtrend and could break below its 52-week low. A minimum holding period of 2-3 years is suggested to ride out the cycle and realize the potential from the Huntsman merger. Earnings visibility is low in the near term, so patience is required.